TORONTO, ON - July 21, 2014 - Blueline Bioscience, a Versant Ventures incubator, has launched a call for proposals for a unique Canadian grant program. The Blueline Drug Target Program will provide up to $150,000 per project to advance the validation of novel drug targets from Canadian academic research institutes. The program provides an opportunity for collaboration between academic researchers and Blueline's team of drug discovery experts, biotechnology entrepreneurs, and venture capital investors. Over the 12 month duration of each funded project, Blueline will advise funded teams on the design of research plans to rigorously evaluate the therapeutic potential of novel targets.